SARS-CoV-2 Antigen Rapid Test
Providing an aid in early diagnosis of individuals who are suspected of COVID-19 by their healthcare provider and who are asymptomatic.
Providing an aid in early diagnosis of individuals who are suspected of COVID-19 by their healthcare provider and who are asymptomatic.
ACON, a leading global of rapid tests, point of care diagnostics and medical devices is pleased to announce that it received FDA Over The Counter (OTC) clearance for its Distinct® Early Detection Pregnancy test.
The test performs the qualitative detection of human chorionic gonadotropin (hCG) in urine and can help users determine a pregnancy as early as 6 days before the day of the missed period.
“We are very happy with the excellent performance of this test” said Jinn-nan Lin, President of ACON,“The test detects hCG levels at lower levels than most products on the market today”
The test results are easy to read and interpret. The test is designed with the user in mind, allowing for a large absorbent tip, and an ergonomic thumb grip.
Distinct® Early Detection Pregnancy test is available for private label opportunities.
The test is FDA Cleared for Over the Counter (OTC) use in the US, and available for distribution in all worldwide markets that recognizes FDA Clearances.